SCHEMBL773863

SCHEMBL773863

Cc1ccc2c(O)cccc2c1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.63
HSD17B1 P14061 10/20 0.59
HSD17B2 P37059 10/20 0.59
PLAU P00749 1/20 0.59
ESR1 P03372 2/20 0.55
ESR2 Q92731 2/20 0.55
KDM4E B2RXH2 1/20 0.48
CYP2A6 P11509 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
TRPA1 O75762 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14417405 0.84 HSD17B1 (0.73) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL14417354 0.83 HSD17B1 (0.70) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL29291203 0.83 CYP1A2 (0.53) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL1402219 0.83 CYP1A2 (0.63) CYP1A2HSD17B1HSD17B2PLAUKDM4E
SCHEMBL12722493 0.80 HSD17B1 (0.49) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL14417221 0.79 HSD17B1 (0.70) CYP1A2HSD17B1HSD17B2PLAUESR1
P-Cresol SCHEMBL5528682 0.79 HSD17B1 (0.56) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL16632676 0.79 CYP1A2 (0.49) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL444105 0.77 HSD17B1 (0.84) CYP1A2HSD17B1HSD17B2PLAUESR1
SCHEMBL15451 0.77 HSD17B1 (0.70) CYP1A2HSD17B1HSD17B2PLAUESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112521317-B Sulfonated naphthol bola type surfactant for oil displacement of heavy oil reservoir as well as synthetic method and application thereof 甘肃智仑新材料科技有限公司 2022-07-15 CN claimed
US-7211414-B2 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity VISIGEN BIOTECHNOLOGIES, INC. (US) 2007-05-01 US claimed
CN-117865925-A 3, 4-benzocoumarin compound based on complex functional aromatic hydrocarbon and preparation method and application thereof 上海瑞苷生物科技有限公司 2024-04-12 CN disclosed
EP-4153555-B1 PHOTOOXIDATION OF PHENOLIC COMPOUNDS DSM IP ASSETS BV (NL) 2024-01-31 EP disclosed
EP-3415641-B1 METHOD FOR ANALYSIS OF MOLECULES PACIFIC BIOSCIENCES CALIFORNIA INC (US) 2023-11-01 EP disclosed
EP-4153555-A1 PHOTOOXIDATION OF PHENOLIC COMPOUNDS DSM IP Assets B.V. (NL) 2023-03-29 EP disclosed
CN-115667201-A Photooxidation of phenolic compounds 帝斯曼知识产权资产管理有限公司 2023-01-31 CN disclosed
US-11492358-B1 Macrocyclic indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-11-08 US disclosed
CN-112521317-B Sulfonated naphthol bola type surfactant for oil displacement of heavy oil reservoir as well as synthetic method and application thereof 甘肃智仑新材料科技有限公司 2022-07-15 CN disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 EP disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
EP-0818512-A1 Quinoline derivative and use of same MITSUI TOATSU CHEMICALS, Inc. (JP) 1998-01-14 EP disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed
US-4772742-A POLYESTER INTERMEDIATES AMOCO CORPORATION (US) 1988-09-20 US disclosed
US-4709080-A POLYESTERS STANDARD OIL COMPANY (US) 1987-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11492358-B1 Macrocyclic indole derivatives CCND2, CCNT2, IDO1 CYP1A2 226/4885HSD17B1 1940/4885HSD17B2 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.